The FDA has approved three cannabinoids as drugs. In this webinar the focus will be on the FDA Meeting on May 31, 2019 Scientific Data and Information about Products Containing Cannabis or Cannabis-Derived Compounds; Public Hearing, and published reactions to it. The current market for CBD will also be discussed.The agency approved Epidiolex (cannabidiol or CBD) oral solution for the treatment of seizures associated with two rare, severe forms of epilepsy.
The FDA has also approved the synthetic cannabinoids dronabinol and nabilone to treat nausea and vomiting associated with cancer chemotherapy in people who have already taken other medicines to treat these symptoms without good results. Cannabinoids are a hot topic in the current pharmaceutical industry. Knowledge of the current FDA approvals and research being reported will assist in predicting the future of this class of compounds and deciding whether a given firm wants to be part of it.
Course Objectives:
This webinar with regulatory compliance expert, Dr. Loren Gelber, Ph.D., will discuss the current status of cannabinoids as medical products in the United States. The focus will be on what we can learn from the FDA approval of Epidolex (Cannabidiol) oral solution 100 mg/mL. You will be provided guidance on how to obtain research information and understand the current market for Cannabidiol (CBD) in the U.S.
This session will include what all statutory or regulatory changes might be needed and what the impact of such marketing would be on the public health.
Course Outline:
• Overview and general information on cannabinoids
• Cannabis as a 'dietary supplement'
• Grounds for the recent approval of Epidolex
• Legal and Illegal marketing of Cannabidiol (CBD)
• Research being conducted on CBD
• How to obtain research information
• Cannabis as 'food'
• Regulatory and future trends for cannabinoids in the United States
What You Get:
• Training Materials
• Live Q&A Session with our Expert
• Participation Certificate
• Access to Signup Community (Optional)
• Reward Points
Who Will Benefit:
• Pharmaceutical Executives
• Pharmaceutical Research and Development
• Pharmaceutical Regulatory Affairs
• Food Research and Development
• Food Executive
• Quality Professionals
• Regulatory Compliance Officer
USP <71> Sterility: New Updates and Harmonization
Get Instant Access 90 Minutes View Program |
Bioavailability and Bioequivalence Studies submitted in NDAs and INDs
Get Instant Access 90 Minutes View Program |
Veterinary Feed Directive (VFD) Final Rule – What you need to know?
Get Instant Access 60 Minutes View Program |
Packaging and Labeling for Commercial and Clinical Products
Get Instant Access 90 Minutes View Program |
Providing DMFs in eCTD format
Get Instant Access 90 Minutes View Program |
Get Instant Access On-Demand Access
Preparing for the ICE Storm: What to Do During I 9 Audits and ICE Raids
Janette S. Levey
Human Resources
Get Instant Access On-Demand Access
OSHA Inspections and Investigations-How to Manage Them
Irwin Dobrushin
Environment Health and Safety | OSHA
Get Instant Access On-Demand Access
29 CFR 1904: OSHA's New Injury Recordkeeping E-Submission Rule
Occupational Safety and Health Administration
Get Instant Access On-Demand Access
Working with Excel Databases: Sort, Filter, Subtotal and More
Cathy Horwitz
Cross Industry | Skill Enhancement
Get Instant Access On-Demand Access
Writing Audit Reports
Jonnie T. Keith CIA, CFE, CGAP, CICA
Governance, Risk and Compliance
Get Instant Access On-Demand Access
BSA Reporting Requirements
Banking and Financial Services Industry
Get Instant Access On-Demand Access
Human Factors-Usability Based on ISO 62366
Medical Device | Diagnostic | Pharmaceutical | Biologics fields
Get Instant Access On-Demand Access
Chat GPT for Project Managers
Charles H. Paul
All FDA Regulated Industry